SPTBN2 and non-small cell lung carcinoma: Our findings indicated that SPTBN2 KO enhanced the sensitivity of NSCLC cells to ferroptosis inducers such as FIN56, RSL3, and Erastin, without affecting the efficacy of other cell death inducers (Fig. 1A).